Cancer Bioshield 2.0 for all cancer types with high TGF-β burden. ImmunityBio, Inc. just filed a patent for a TGFβ-trap (US20250195614). $IBRX HCW9218 is already in a Phase I/II trial for advanced pancreatic cancer (NCT05304936), and would integrate well into the Cancer Bioshield.

$IBRX Anktiva is approved in the UK! gov.uk/government/new…

$IBRX Wonderful attitude and good luck in the third round.👏👍👊

$IBRX ResQ117EX-ALC as the first Lymphopenia trial: First Anktiva trial for early-stage cancer. First Anktiva trial that is not limited to late-stage cancer, where the immune system is already compromised by chemotherapy and radiation, which can hinder Anktiva's effectiveness.

$IBRX ResQ117EX-ALC Lymphopenia trial: No specific cancer type is mentioned; all types are eligible to participate in the trial. This makes it the first universal Anktiva trial. It is also the first trial involving non-metastatic, minimally treated patients receiving Anktiva.

$IBRX ResQ117EX-ALC Lymphopenia trial: Absolute Lymphocyte Count is a proven and inexpensive, biomarker accessible to everyone. Eligibility criteria are: - ALC < 1500 before first-line treatment - or ALC < 1000 during or after progression following first-line therapy

$IBRX

$IBRX The next Cancer Therapy. Great explanation of GretchMick on her #Bioshield therapy. - Targeting: CEA adenovirus vaccine (Tri-Ad5) targets NK cells to the tumor. - Stimulation: Anktiva stimulates NK-, T-, and memory T-cells. - Less harm to NK-cells : Chemo Capecitabine

$IBRX BioShield platform, what's next? Consider a regulatory disruption to a Bioshield Master IND platform, a ligand-driven, modular immunopatform, and what should be done now? ImmunityBio, Inc. Dr. Pat Soon-Shiong cloud.hoststar.ch/s/zww7Qd3x2YMx…

$IBRX Somebody else told you so?

$IBRX

The Bioshield strategy is explained briefly and clearly. ImmunityBio, Inc. $IBRX youtube.com/watch?v=2G1ntN…

$IBRX Bladder Cancer: Duration matters

$IBRX

Congratulations! Information is available in my previous post. NantIQ is a trademark of NantHealth, not a specific product. $IBRX x.com/MK2forU/status…

Explaining the IT/AI backbone of $IBRX precision medicine. My post from 2024. cloud.hoststar.ch/s/T6ikqbNRwwK8…

Glad to hear you’re doing well. $IBRX

$IBRX LONG COVID The study plan for the Interrupt_LC trial (NCT07108036; Phase 2; COVID-4.018-LONG) to assess the safety and tolerability of Anktiva (N-803) in patients with Long Covid is now available online. clinicaltrials.gov/study/NCT07108…

$IBRX

Post Bioshield Test Results! #cancersurveillance #cancer #coloncancer #chemo #bioshield $IBRX ImmunityBio, Inc. Colorectal Cancer Alliance